Girometti, N;
Jones, R;
Levy, J;
McCormack, S;
Sullivan, A;
Barber, TJ;
(2016)
Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
AIDS
, 30
(13)
pp. 2131-2133.
10.1097/QAD.0000000000001171.
Preview |
Text
McCormack_00002030-900000000-97750.pdf Download (397kB) | Preview |
Abstract
Renal toxicity in a 73 year old man using tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) is described. Reduced renal reserve, a higher exposure to co-medications and co-morbidities can present a challenge when assessing the risks and benefits of tenofovir based PrEP in the ageing population.
| Type: | Article |
|---|---|
| Title: | Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/QAD.0000000000001171 |
| Publisher version: | http://dx.doi.org/10.1097/QAD.0000000000001171 |
| Language: | English |
| Additional information: | This is a non-final version of an article published in final form in: Girometti, N; Jones, R; Levy, J; McCormack, S; Sullivan, A; Barber, TJ; (2016) Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities. AIDS, 30 (13) pp. 2131-2133. 10.1097/QAD.0000000000001171. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1497969 |
Archive Staff Only
 |
View Item |
